With the recent announcement that it had reached a settlement in its patent dispute with Samsung Bioepis, AbbVie has scored another significant victory in efforts to delay market entry to biosimilar versions of its drug, Humira. While allowing Samsung to launch its product in European jurisdictions later this year, the deal keeps the copycat arthritis treatment out of the lucrative US market until 2023.

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

Excellent articles and focus on best practices.

Ruud Peters
Advisor
Philips Intellectual Property & Standards

Benefits

Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?